76 mg
Trade Name
Elrexfio
Solution for injection
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.